コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 val analysis, and reduction in the number of antiglaucoma medications.
2 ar pressure, which responded well to topical antiglaucoma medications.
3 ucoma medications in the absence of systemic antiglaucoma medications.
4 therefore represents a potential target for antiglaucoma medications.
5 defined as IOP </= 12 mm Hg without and with antiglaucoma medications (absolute success and qualified
7 pressure reduction of at least 20%, without antiglaucoma medication, and without any additional inte
8 ressants, antiepileptic medications, topical antiglaucoma medications, and chemotherapeutic/immunosup
9 ine IOP was 17.9 +/- 3.3 mm Hg and number of antiglaucoma medications at baseline was 2.0 +/- 1.0.
11 oma medications to 9.6 +/- 2.7 mm Hg with no antiglaucoma medications at the final visit (P < .001 an
12 tions to 13.6 +/- 3.2 mm Hg with 0.2 +/- 0.5 antiglaucoma medications at the last visit (P < .001 and
15 ion of IOP of >3 mm Hg and 20% and number of antiglaucoma medications equal to or less than baseline.
16 al field (VF) mean deviation (MD), number of antiglaucoma medications, history of glaucoma surgery, a
17 least 1 week apart) with or without topical antiglaucoma medications in the absence of systemic anti
19 plication for intracameral administration of antiglaucoma medications, this study, for the first time
21 ved from 21.9 +/- 7.9 mm Hg with 2.7 +/- 0.8 antiglaucoma medications to 13.6 +/- 3.2 mm Hg with 0.2
22 ved from 23.3 +/- 4.9 mm Hg with 2.6 +/- 0.7 antiglaucoma medications to 9.6 +/- 2.7 mm Hg with no an
24 number of recent publications document that antiglaucoma medications with a long duration of action
25 32 contralateral glaucomatous eyes receiving antiglaucoma medications without any previous glaucoma s
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。